MNTA News and Press, Momenta Pharmaceuticals Inc. From 08/19/20

Thinly traded argenx SE (NASDAQ: ARGX ) perks up  1%  premarket on light volume on the heels of Johnson & Johnson's (NYSE: JNJ ) $6.5B takeout of Momenta Pharmaceuticals (NASDAQ: MNTA ) . More news on: argenx SE, Johnson & Johnson, Momenta Pharmaceuticals, Inc., He...

Johnson & Johnson (NYSE: JNJ ) has agreed to acquire Momenta Pharmaceuticals (NASDAQ: MNTA ) for $52.50 per share in cash for a total of $6.5B. More news on: Johnson & Johnson, Momenta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisition...

Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020 Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatme...

Without any meaningful revenue, Momenta Pharmaceuticals ' (NASDAQ: MNTA) second-quarter report was rather uneventful, so it's a little surprising to see shares down 13.5% today without any significant news.But perhaps the lack of news is what's making short-term investors head for the exits. ...

Momenta Pharmaceuticals, Inc. (MNTA) Q2 2020 Results Conference Call August 10, 2020 08:30 AM ET Company Participants Patty Eisenhaur - VP, IR and Corporate Communication Craig Wheeler - President and CEO Young Kwon - Chief Financial and Business Officer Santiago Arroyo - Chief...

Gainers:  Seres Therapeutics (NASDAQ: MCRB ) +356% . More news on: Seres Therapeutics, Inc., Xtant Medical Holdings, Inc., BiomX Inc., Stocks on the move, , Read more ...

The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Momenta Pharmaceuticals (NASDAQ: MNTA ) : Q2 GAAP EPS of -$0.48 misses by $0.07 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between IgG reduction and MG-ADL clinical benefit in MG; full data expected by Q4 2020 – ...

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results...